Azenta, Inc.
AZTAHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframePart of the healthcare sector, Azenta, Inc. (AZTA) is listed under Medical Instruments & Supplies. At a $1.37B market cap, Azenta, Inc. ranks as a small-cap company within healthcare. It operates through Sample Management Solutions and Multiomics segments.
Market Cap
$1.37B
Beta
1.39
P/E (TTM)
—
P/E (Fwd)
53.33
EPS (TTM)
$-2.46
EPS (Fwd)
$0.59
ROE
-7.0%
ROA
-0.7%
Cash
$325.8M
Total Debt
$54.0M
Free CF
$63.4M
52W Change
6.4%
Annual Financials
Cash vs Debt
Where AZTA stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, AZTA finished 29.42% above its 150-day moving average ($25.97) and 18.93% above its 200-day moving average ($28.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AZTA overbought or oversold?
At the August 28, 2026 close, AZTA's RSI(14) was 56.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Azenta, Inc. holds $325.8M in cash against $54.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $63.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -7.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $555.5M (2022) to $593.8M (2025).
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Azenta, Inc.'s trajectory.